How a specific receptor affects inflammation in the immune system

The impact of Aryl hydrocarbon receptor signaling on Toll like receptor-mediated inflammation

NIH-funded research University of California at Davis · NIH-10993603

This study is looking at how a specific protein in our bodies, called the aryl hydrocarbon receptor, affects our immune system and how exposure to certain environmental toxins might cause problems like asthma and autoimmune diseases, with the hope of finding new ways to help people feel better.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of California at Davis NIH-funded
Lab location1 site (Davis, United States)
Project IDNIH-10993603 on NIH RePORTER

What this research studies

This research investigates the role of the aryl hydrocarbon receptor (AhR) in regulating immune responses, particularly how exposure to certain environmental toxins can disrupt normal immune function. By studying the interactions between AhR and other signaling pathways, such as Toll-like receptors, the research aims to uncover the mechanisms behind immune system disorders. Patients may benefit from a better understanding of how these pathways contribute to conditions like asthma and autoimmune diseases, potentially leading to new therapeutic strategies. The research involves advanced techniques to analyze gene expression and immune cell behavior.

Who could benefit from this research

Good fit: Ideal candidates for this research include individuals with autoimmune conditions or allergies, particularly those affected by environmental toxins.

Not a fit: Patients with non-immune related conditions or those not exposed to relevant environmental toxins may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new treatments for autoimmune diseases and allergies by targeting the pathways involved in immune regulation.

How similar studies have performed: Previous research has shown that targeting immune signaling pathways can lead to significant advancements in treating autoimmune diseases, suggesting a promising avenue for this investigation.

Where this research is happening

Davis, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Autoimmune Diseases
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.